Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR2E1 | Q9Y466 | 13/20 | 0.54 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.38 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.38 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.38 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12372948 | 0.91 | NR2E1 (0.58) | NR2E1CYP2E1CYP2A6CYP1A2CYP3A4 | |
| SCHEMBL10104281 | 0.85 | NR2E1 (0.73) | NR2E1 | |
| SCHEMBL21902011 | 0.84 | NR2E1 (0.51) | NR2E1CYP2E1CYP2A6CYP1A2CYP3A4 | |
| SCHEMBL9609575 | 0.84 | NR2E1 (0.71) | NR2E1 | |
| SCHEMBL21849215 | 0.80 | NOTUM (0.37) | NR2E1CYP1A2CYP2D6CYP2C9PTK2 | |
| SCHEMBL15315527 | 0.79 | CYP2C19 (0.36) | NR2E1CYP1A2CYP2C19NTRK1DDR1 | |
| SCHEMBL22604349 | 0.79 | CYP2E1 (0.51) | NR2E1CYP2E1CYP2A6CYP1A2CYP3A4 | |
| SCHEMBL10183719 | 0.79 | CYP2E1 (0.51) | NR2E1CYP2E1CYP2A6CYP1A2CYP3A4 | |
| SCHEMBL270618 | 0.77 | CYP1A2 (0.53) | NR2E1CYP2E1CYP2A6CYP1A2CYP3A4 | |
| SCHEMBL10310480 | 0.76 | NR2E1 (0.45) | NR2E1CYP2E1CYP2A6CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180215734-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIOSCIENCE, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180155327-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | NANTBIOSCIENCE, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20170349588-A1 | 1H-1,8-NAPHTHYRIDIN-2-ONES AS ANTI PROLIFERATIVE COMPOUNDS | NATCO PHARMA LIMITED (IN) | 2017-12-07 | — | — | US | disclosed |
| US-9765072-B2 | 1H-1,8-naphthyridin-2ones as anti proliferative compounds | NATCO PHARMA LIMITED (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170114057-A1 | 1H-1,8-NAPHTHYRIDIN-2ONES AS ANTI PROLIFERATIVE COMPOUNDS | NATCO PHARMA LIMITED (IN) | 2017-04-27 | — | — | US | disclosed |
| US-8841318-B2 | Substituted heterocycles as janus kinase inhibitors | INCYTE CORPORATION (US) | 2014-09-23 | — | — | US | disclosed |
| US-20130274257-A1 | SUBSTITUTED HETEROCYCLES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349588-A1 | 1H-1,8-NAPHTHYRIDIN-2-ONES AS ANTI PROLIFERATIVE COMPOUNDS | ABL1, MKI67, MCL1 | NR2E1 1283/4885CYP2E1 1395/4885CYP2A6 2141/4885 |
| US-20180215734-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | DCK, TK1, DTYMK | NR2E1 2458/4885CYP2E1 4424/4885CYP2A6 3398/4885 |
| US-20180155327-A1 | PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS | DCK, TK1, DTYMK | NR2E1 3413/4885CYP2E1 4536/4885CYP2A6 3717/4885 |
| US-20170114057-A1 | 1H-1,8-NAPHTHYRIDIN-2ONES AS ANTI PROLIFERATIVE COMPOUNDS | ABL1, MKI67, ABL2 | NR2E1 1510/4885CYP2E1 1310/4885CYP2A6 1399/4885 |
| US-20130274257-A1 | SUBSTITUTED HETEROCYCLES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | NR2E1 1561/4885CYP2E1 2042/4885CYP2A6 2552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.